ClinicalTrials.gg
CompletedNCT01167153EXAMUpdated Jun 1, 2012Results posted

Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients

A Phase 4 interventional study of Valsartan/Amlodipine and Nifedipine in Hypertension, sponsored by Novartis. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-06-01.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
564
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
35th of 139
564 · median 198
Started
2010
with 2 others
Phase 4
67 of 140
none open now
Registered
108th of 140
by date
Lead sponsor
69 of 140
Novartis

Among the 140 studies testing valsartan in Hypertension, this one is the 35th largest by enrollment of the 139 interventional ones that give a count, is one of 3 that started in 2010, is one of 67 in phase 4, and was the 108th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this study was to compare the efficacy and safety of Valsartan/Amlodipine (EXforge®) with nifedipine, as well as vascular function index.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • Valsartan Amlodipine single pill combination
  • BP control
  • ABPM
  • Hypertensive patients not adequately controlled by mono antihypertensive drugs
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy (initial dose of Angiotensin Receptor Blockers (ARB), Angiotensin Converting Enzyme Inhibitors (ACEI), Calcium Channel Blockers (CCB), diuretics or β receptor blocker)

Exclusion criteria

Exclusion Criteria:

  • Systolic BP (SBP) level ≥160 mm Hg (≥160 mm Hg in diabetics) or a diastolic BP (DBP) level ≥110 mm Hg (≥100 mm Hg in diabetics) at any time between screening and randomization.
  • Patients with type 1 diabetes or poorly controlled type 2 diabetes (glycosylated >8.0%)
  • Patients had evidence of hepatic disease or renal impairment
  • Other exclusion criteria included evidence of secondary hypertension or history of cardio-vascular disease.
  • Women who were pregnant, nursing, or of and not using acceptable .

Other protocol-defined inclusion/exclusion criteria applied.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
564 participants (actual)

Study arms

  • Experimental
    Valsartan/amlodipine

    Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.

    Drug: Valsartan/Amlodipine

  • Active comparator
    Nifedipine

    Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.

    Drug: Nifedipine

Interventions

  • DrugValsartan/Amlodipine

    Drug pages: Valsartan · Amlodipine

    Valsartan/Amlodipine 80/5mg single pill combination (SPC)

    Also known as: Exforge®

  • Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg

    Also known as: Adalat

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)

    The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher mean sitting diastolic blood pressure (MSDBP) was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.

    Time frame: Baseline, 12 weeks

  2. Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks)

    The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher msDBP was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Percentage of Patients With Effective Systolic Blood Pressure (SBP) Control Rate and Effective Diastolic Blood Pressure (DBP) Control Rate at the Study End Point (12 Weeks)

    Effective SBP control rate was defined as proportion of subjects in whom MSSBP \< 140 mmHg or MSSBP reduction ≥ 20 mmHg from baseline. Effective DBP control rate was defined as proportion of subjects in whom MSDBP \< 90 mmHg or MSDBP reduction ≥10 mmHg from baseline.

    Time frame: Baseline, 12 weeks

  2. Percentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks

    Blood Pressure (BP) target was defined as mean sitting BP\<140/90 mm Hg in non-diabetic patients and\<130/80 mm Hg in diabetic patients at 12 weeks.

    Time frame: 12 weeks

  3. Change From Baseline in Orthostatic SBP and DBP at 12 Weeks

    The arm with higher sitting blood pressure was selected for all examinations throughout the study. Orthostatic blood pressure was measured when subject stood for 1 minute. Orthostatic blood pressures were measured at screening and each visit.

    Time frame: Baseline, 12 weeks

  4. Change From Baseline in Sitting Pulse at 12 Weeks

    Sitting pulse was measured by sphygmomanometer after subject sat for 5 minutes at clinic during each visit.

    Time frame: Baseline, 12 weeks

  5. Change From Baseline in Orthostatic Pulse at 12 Weeks

    Orthostatic pulse was measured by sphygmomanometer when subject stood for 1 minute at clinic during each visit.

    Time frame: Baseline, 12 weeks

07

Results

Posted Jun 1, 2012

Participant flow

Participant flow — Overall Study
MilestoneValsartan/AmlodipineNifedipine
Started282282
Intention to treat (itt)272268
Completed264249
Not completed1833
Withdrew: Non-effective therapy14
Withdrew: Ae including clinical laboratory ae28
Withdrew: Hypotension10
Withdrew: Lost to follow-up79
Withdrew: Non-compliance to concomitant medication02
Withdrew: Investigator initiation withdrawal,other11
Withdrew: Withdrawal consent11
Withdrew: Subject initiation withdrawal, other58

Outcome measures

PrimaryChange From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)

The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher mean sitting diastolic blood pressure (MSDBP) was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · mm Hg
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)
mm HgValsartan/AmlodipineNifedipine
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)-16.8 ± 11.69-10.6 ± 12.02
PrimaryChange From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks)

The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher msDBP was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · mm Hg
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks)
mm HgValsartan/AmlodipineNifedipine
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks)-8.5 ± 8.52-4.8 ± 8.89
SecondaryPercentage of Patients With Effective Systolic Blood Pressure (SBP) Control Rate and Effective Diastolic Blood Pressure (DBP) Control Rate at the Study End Point (12 Weeks)

Effective SBP control rate was defined as proportion of subjects in whom MSSBP \< 140 mmHg or MSSBP reduction ≥ 20 mmHg from baseline. Effective DBP control rate was defined as proportion of subjects in whom MSDBP \< 90 mmHg or MSDBP reduction ≥10 mmHg from baseline.

Time frame:
Baseline, 12 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Effective Systolic Blood Pressure (SBP) Control Rate and Effective Diastolic Blood Pressure (DBP) Control Rate at the Study End Point (12 Weeks)
Percentage of participantsValsartan/AmlodipineNifedipine
Achieving Effective SBP Control82.4063.40
Achieving Effective DBP Control92.8876.98
SecondaryPercentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks

Blood Pressure (BP) target was defined as mean sitting BP\<140/90 mm Hg in non-diabetic patients and\<130/80 mm Hg in diabetic patients at 12 weeks.

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks
Percentage of participantsValsartan/AmlodipineNifedipine
Percentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks79.0357.36
SecondaryChange From Baseline in Orthostatic SBP and DBP at 12 Weeks

The arm with higher sitting blood pressure was selected for all examinations throughout the study. Orthostatic blood pressure was measured when subject stood for 1 minute. Orthostatic blood pressures were measured at screening and each visit.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · mm Hg
Change From Baseline in Orthostatic SBP and DBP at 12 Weeks
mm HgValsartan/AmlodipineNifedipine
Orthostatic diastolic blood pressure-7.2 ± 9.43-3.3 ± 9.58
Orthostatic systolic blood pressure-13.3 ± 13.86-8.6 ± 13.98
SecondaryChange From Baseline in Sitting Pulse at 12 Weeks

Sitting pulse was measured by sphygmomanometer after subject sat for 5 minutes at clinic during each visit.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · beats/min
Change From Baseline in Sitting Pulse at 12 Weeks
beats/minValsartan/AmlodipineNifedipine
Change From Baseline in Sitting Pulse at 12 Weeks-1.1 ± 8.490.0 ± 8.22
SecondaryChange From Baseline in Orthostatic Pulse at 12 Weeks

Orthostatic pulse was measured by sphygmomanometer when subject stood for 1 minute at clinic during each visit.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · beats/min
Change From Baseline in Orthostatic Pulse at 12 Weeks
beats/minValsartan/AmlodipineNifedipine
Change From Baseline in Orthostatic Pulse at 12 Weeks-0.6 ± 8.930.4 ± 8.48

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan/Amlodipine—0/282 (0%)14/282 (5%)
Nifedipine—1/282 (0.4%)32/282 (11.3%)
Most frequent serious events
Most frequent serious events
EventValsartan/AmlodipineNifedipine
Unstable Blood PressureCardiac disorders0/2821/282
Most frequent other events
Most frequent other events
EventValsartan/AmlodipineNifedipine
HeadacheNervous system disorders6/28220/282
DizzyNervous system disorders11/28215/282

Baseline characteristics

Age Continuous
Age Continuous(years)Valsartan/AmlodipineNifedipineTotal
Mean53.8 ± 8.5953.1 ± 8.7253.5 ± 8.63
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan/AmlodipineNifedipineTotal
Female135135270
Male137133270
08

Study locations

1 site
  • Novartis Pharmaceuticals
    Beijing, China
09

References and documents

Publications

  • Xu SK, Zeng WF, Li Y, Chen LL, Xie JH, Wang JG. Effects of the valsartan/amlodipine combination and nifedipine gastrointestinal therapeutic system monotherapy on brachial pulse pressure and radial augmentation index in hypertensive patients. Blood Press Monit. 2021 Aug 1;26(4):251-256. doi: 10.1097/MBP.0000000000000527. PubMed 33734121 ↗
  • Wang JG, Zeng WF, He YS, Chen LL, Wei M, Li ZP, Zhang BW, Li Y; EXAM Investigators. Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy. Adv Ther. 2013 Aug;30(8):771-83. doi: 10.1007/s12325-013-0048-x. Epub 2013 Aug 21. PubMed 23963546 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2010
First posted
Jul 22, 2010
Start
May 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
Jun 1, 2012
Last update
Jun 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01167153
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Jul 22, 2010
Start date
May 2010
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Jun 1, 2012
Last update
Jun 1, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Amlodipine

Start the discussion